# A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion

> **NCT05143463** · PHASE1 · COMPLETED · sponsor: **Neuracle Science Co., LTD.** · enrollment: 64 (actual)

## Conditions studied

- Neurodegenerative Diseases

## Interventions

- **DRUG:** NS101 IV infusion

## Key facts

- **NCT ID:** NCT05143463
- **Lead sponsor:** Neuracle Science Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-04
- **Primary completion:** 2022-08-19
- **Final completion:** 2022-12-22
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05143463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05143463, "A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05143463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*